These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 28652105)

  • 21. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
    Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
    Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
    Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
    Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 31. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
    Mair J; Lindahl B; Giannitsis E; Huber K; Thygesen K; Plebani M; Möckel M; Müller C; Jaffe AS;
    Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):321-328. PubMed ID: 26758541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
    Maisel AS; Daniels LB; Anand IS; McCullough PA; Chow SL
    Postgrad Med; 2018 Apr; 130(3):299-307. PubMed ID: 29596012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin Receptor-Neprilysin Inhibitor Suppresses Renin-Angiotensin-Aldosterone System Activation After Cardiac Surgery Using Cardiopulmonary Bypass.
    Hoshino J; Saito S; Shibasaki I; Sairenchi T; Okubo S; Matsuoka T; Hirota S; Yokoyama S; Kanazawa Y; Tezuka M; Takei Y; Tsuchiya G; Konishi T; Ogata K; Fukuda H
    Circ J; 2024 Aug; 88(9):1406-1415. PubMed ID: 38658351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
    Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
    Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.